News

Voyager Therapeutics Inc. Announces New License Agreement with Novartis Pharma AG

1 Mins read

Voyager Therapeutics Inc.’s stock VYGR soared 32% early Tuesday, following the announcement of a new license agreement with Novartis Pharma AG, a unit of Novartis AG NVS. The collaboration aims to advance potential gene therapies for Huntington’s disease and spinal muscular atrophy. As part of the agreement, Voyager will grant Novartis access to its Tracer capsids and other intellectual property.

Significant Financial Benefits

The deal brings Voyager an upfront payment of $100 million, which includes $20 million for newly issued equity. Additionally, Voyager stands to receive up to $1.2 billion in milestones related to preclinical development, regulatory approvals, and sales achievements. Furthermore, Voyager will be entitled to tiered royalties on global net sales of products that are developed using its technology.

Clear Responsibilities

Under the terms of the agreement, Voyager will be responsible for advancing the preclinical aspects of the project, while Novartis will take charge of all clinical development and commercialization efforts for the Huntington’s disease program.

Promising Performance

Voyager Therapeutics Inc.’s stock has demonstrated impressive growth over the past 12 months, with a 38% increase. In comparison, the S&P 500 has only gained 24% during the same period.

Stay tuned for more updates on Voyager Therapeutics Inc.’s groundbreaking collaboration with Novartis Pharma AG in the field of gene therapies for Huntington’s disease and spinal muscular atrophy.

Related posts
News

First Solar Inc. Financial Report

1 Mins read
First Solar Inc. saw its shares rise more than 5% during the extended session on Tuesday, showing investor optimism for the future…
News

AMC Entertainment Holdings Inc. Quarterly Results Awaited

1 Mins read
Shares of AMC Entertainment Holdings Inc. have surged 5.9% on Tuesday, marking a three-day winning streak and the largest daily percentage increase…
News

Theratechnologies FDA Rejection

1 Mins read
Theratechnologies is poised for a significant setback as the Food and Drug Administration (FDA) has rejected its supplemental biologics license application for…

Leave a Reply

Your email address will not be published. Required fields are marked *

4 + 5 =